In Utero Tenofovir Exposure Is not Associated with Fetal Long Bone Growth

Clinical Infectious Diseases

Volumn 62, Issue 12, 2016, Pages 1604-1609

  Jao, Jennifer ^a   Abrams, Elaine J ^b,c   Phillips, Tamsin ^d   Petro, Greg ^d   Zerbe, Allison ^b   Myer, Landon ^d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b University of Cape Town ^*  (United States)

^c NONE   (United States)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

femur; fetal; humerus; pregnancy; tenofovir

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BONE GROWTH; CD4 LYMPHOCYTE COUNT; CONCEPTION; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; FEMUR; FETUS GROWTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMERUS; MAJOR CLINICAL STUDY; PREGNANCY DIABETES MELLITUS; PREGNANT WOMAN; PRIORITY JOURNAL; SOUTH AFRICA; BONE DEVELOPMENT; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FETUS DEVELOPMENT; FOLLOW UP; HIV INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

ADULT; ANTI-HIV AGENTS; BONE DEVELOPMENT; CLINICAL TRIALS AS TOPIC; FEMALE; FEMUR; FETAL DEVELOPMENT; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; HUMERUS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TENOFOVIR;

EID: 84973452366     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw159     Document Type: Article

References (28)

1. WorldHealth Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: World Health Organization Press, 2013. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/en/. Accessed 30 October 2014.
2. World Health Organization. Antiretroviral therapy for HIV infections in adults and adolescents: recommendations for a public health approach. 2010 Revision. Geneva, Switzerland: World Health Organization, 2010.
3. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009. Available at: http://www.who.int/hiv/pub/ 2009progressreport/en/. Accessed 10 May 2013.
4. World Health Organization. Progress report 2011: global HIV/AIDS response. Available at http://www.who.int/hiv/pub/progress-report2011/en/. Accessed 6 November 2014.
5. Stek AM. Antiretroviral treatment in pregnancy. Curr Opin HIV AIDS 2008; 3:155-60.
6. Thorne C, Newell ML. The safety of antiretroviral drugs in pregnancy. Expert Opin Drug Saf 2005; 4:323-35.
7. Watts DH, Covington DL, Beckerman K, et al. Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy. Am J Obstet Gynecol 2004; 191:985-92.
8. Geremia C, Cianfarani S. Insulin sensitivity in children born small for gestational age (SGA). Rev Diabet Stud 2004; 1:58-65.
9. Barker DJ, Winter PD, Osmond C, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet 1989; 2:577-80.
10. Jaquet D, Collin D, Levy-Marchal C, Czernichow P. Adult height distribution in subjects born small for gestational age. Horm Res 2004; 62:92-6.
11. Levy-Marchal C, Jaquet D. Long-term metabolic consequences of being born small for gestational age. Pediatr Diabetes 2004; 5:147-53.
12. Tarantal AF, Castillo A, Ekert JE, Bischofberger N, Martin RB. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29:207-20.
13. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292:191-201.
14. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008; 19:913-8.
15. Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118: e711-8.
16. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152:582-4.
17. Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:323-33.
18. Siberry GK,Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151-9.
19. Himes SK, Wu JW, Jacobson DL, et al. Meconium tenofovir concentrations and growth and bone outcomes in prenatally tenofovir exposed HIV-uninfected children. Pediatr Infect Dis J 2015; 34:851-7.
20. Chitty LS, Altman DG. Charts of fetal size: limb bones. BJOG 2002; 109:919-29.
21. Villar J, Cheikh Ismail L, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet 2014; 384:857-68.
22. Hadlock FP, Deter RL, Harrist RB, Park SK. Estimating fetal age: computerassisted analysis of multiple fetal growth parameters. Radiology 1984; 152: 497-501.
23. Ransom CE, Huo Y, Patel K, et al. Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. J Acquir Immune Defic Syndr 2013; 64:374-81.
24. Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIVinfected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012; 9:e1001217.
25. Bronner F, Farach-Carson M. Bone formation. London, United Kingdom, and New York, NY: Springer, 2004.
26. Siberry GK, Jacobson DL, Kalkwarf HJ, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis 2015; 61:996-1003.
27. Vigano A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011; 16:1259-66.
28. Harvey NC, Mahon PA, Robinson SM, et al. Different indices of fetal growth predict bone size and volumetric density at 4 years of age. J Bone Miner Res 2010; 25:920-7.